ArticleJournal of materials chemistry. B2014
Dextran coated bismuth-iron oxide nanohybrid contrast agents for computed tomography and magnetic resonance imaging.
Article in Journal of materials chemistry. B, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 126 citations in OpenAlex.
- Multifunctional Nano-Contrast Agent Carriers: From Traditional Platforms to Next-Generation Theranostic Applications in Molecular Imaging.Biomedicines · 2026Review
- Sustainable earth-abundant bismuth catalytic nanointerfaces using biopolymeric silk fibroin for efficient pollutant reduction.RSC advances · 2026Article
- Scalable flow synthesis of ultrasmall inorganic nanoparticles for biomedical applications via a confined impinging jet mixer.Scientific reports · 2026Article
- Radiotherapy-chemodynamic cancer therapy using bismuth-based nanoparticles: a synergistic approach for enhanced cancer treatment.RSC advances · 2025Review
- Emerging nanoparticle-based x-ray imaging contrast agents for breast cancer screening.Nanomedicine (London, England) · 2025Review
- Towards the clinical translation of a silver sulfide nanoparticle contrast agent: large scale production with a highly parallelized microfluidic chip.European journal of nuclear medicine and molecular imaging · 2025Article
- Article
- Molecular imaging nanoprobes and their applications in atherosclerosis diagnosis.Theranostics · 2024Review
- Nanomaterial-based contrast agents.Nature reviews. Methods primers · 2023Article
- Albumin-Functionalized Iron Oxide Nanoparticles for Theranostics: Engineering and Long-Term In Situ Imaging.Pharmaceutics · 2022Article
- Recent advances in engineering iron oxide nanoparticles for effective magnetic resonance imaging.Bioactive materials · 2022Review
- Facile Fabrication of BiFNanoscale research letters · 2021Article
- Imaging Constructs: The Rise of Iron Oxide Nanoparticles.Molecules (Basel, Switzerland) · 2021Review
- Review
- Illuminating the Brain With X-Rays: Contributions and Future Perspectives of High-Resolution Microtomography to Neuroscience.Frontiers in neuroscience · 2021Review
- Precision targeting of bacterial pathogen via bi-functional nanozyme activated by biofilm microenvironment.Biomaterials · 2021Article
- A Short Review on Biomedical Applications of Nanostructured Bismuth Oxide and Related Nanomaterials.Materials (Basel, Switzerland) · 2020Review
- Nanoparticle contrast agents for X-ray imaging applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Article
- A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials.International journal of nanomedicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Bismuth nanoparticles have been proposed as a novel CT contrast agent, however few syntheses of biocompatible bismuth nanoparticles have been achieved. We herein report the synthesis of composite bismuth-iron oxide nanoparticles (BION) that are based on a clinically approved, dextran-coated iron oxide formulation; the particles have the advantage of acting as contrast agents for both CT and MRI. BION were synthesized and characterized using various analytical methods. BION CT phantom images revealed that the X-ray attenuation of the different formulations was dependent upon the amount of bismuth present in the nanoparticle, while T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.